The proto-oncogene c-MET, a bona fide therapeutic target in human malignancies, including pancreatic cancer (reviewed in Cecchi et al., 2012), is upregulated in KRAS-mutant SW48 cells versus isogenic controls (Figure 7A). This evidence concerns the gene KRAS and familial pancreatic carcinoma.